ライフサイエンスコーパス: median overall survival

1 and is associated with significantly longer median overall survival.

2 ared with matched controls with de novo AML (median overall survival, 1.2 years v 2.9 years; P = .06)

3 herapy (HR 0.58 [95% CI 0.36-0.94], p=0.026; median overall survival 10.7 months [95% CI 6.5-18.9] vs

4 etween groups (0.962, 0.801-1.156, p=0.6757; median overall survival 11.2 months [9.9-11.9] in the ra

5 iotherapy (0.59 [95% CI 0.36-0.96], p=0.034; median overall survival 11.6 months [95% CI 6.5-20.5] vs

6 The latter was associated with a prolonged median overall survival (11.6 vs. 6.6 mo, P = 0.02).

7 lso had improved survival with atezolizumab (median overall survival 12.6 months vs 8.9 months; HR 0.

8 tion, there were significant improvements in median overall survival (18.6 months [95% CI 16.0-21.2]

9 ee survival (11.1 months [95% CI 9.7-12.9]), median overall survival (25.6 months [23.1-34.3]), 1-yea

10 nk p=0.030), as well as significantly longer median overall survival (37.5 months [26-not reached] vs

11 to OE cohort from NCDB with no difference in median overall survival (63 vs 53 months; P = 0.130).

12 rence (59 of 686 [8.6%]; P = .02) and longer median overall survival (75.9 months; P < .001).

13 nt groups in the overall patient population (median overall survival 8.8 months [95% CI 7.4-9.6] in t

14 dian follow-up of 7.6 months (IQR 4.0-12.5), median overall survival (8.5 months [95% CI 7.0-10.6] vs

15 rtion score >=50% was associated with longer median overall survival (95% CI) versus tumour proportio

16 Median progression-free survival (PFS) and median overall survival after BTKi initiation were 34 mo

17 Median overall survival after detection of intestinal me

18 Median overall survival after osimertinib progression wa

19 Median overall survival after radioembolization was 35 w

20 The median overall survival after resection was 13.70 months

21 The median overall survival after resection was only 10 mo f

22 verall response typically less than 10%, and median overall survival after third-line therapy of 5-9

23 In the poor prognosis subgroup, median overall survival also did not differ between the

24 Median overall survival among relapsed/refractory patien

25 Median overall survival and conditional survival were 3.

26 Median overall survival and PFS for all patients were 25

27 Median overall survival and progression-free survival, o

28 The median overall survival and treatment duration were 85.8

29 Improved median overall survival approached statistical significa

30 Median overall survival at clinical cutoff (1,337 deaths

31 The unadjusted median overall survival by facility volume was: Q1: 26.9

32 Median overall survival by intention to treat was 16.0 m

33 l, PT2385 single-agent treatment did improve median overall survival compared to placebo (p = 0.04, n

34 tients with WDTC was associated with shorter median overall survival compared with matched controls (

35 Ninety-day mortality was 4.9% and median overall survival, CSS, and RFS were 39, 42, and 1

36 rapy and biologic agents, at which point the median overall survival declines to 4-5 mo.

37 Median overall survival did not differ between patients

38 However, median overall survival did not differ between the patie

39 Median overall survival did not differ significantly bet

40 [95% CI, 1.7-5.2]; p = 0.002), and a longer median overall survival duration (7.3 months [95% CI, 4.

41 The median overall survival duration was significantly longe

42 30-day postoperative mortality was 1.5%.The median overall survival following R0, R1, and R2 resecti

43 The median overall survival for all patients was 21.7 months

44 The median overall survival for children with diffuse intrin

45 Median overall survival for CP-A patients was 13.3 mo (9

46 Median overall survival for metastatic triple-negative b

47 The median overall survival for patients in the gemcitabine

48 The median overall survival for patients with ETP-ALL/LBL wa

49 median follow-up of 4.9 years (IQR 3.9-8.4), median overall survival for patients with myelodysplasti

50 Median overall survival for RP2D treated evaluable popul

51 The median overall survival for the three risk-groups was 45

52 ents with metastatic soft-tissue sarcoma and median overall survival for those treated is 12-16 month

53 In 59 studied patients with BPDCN, the median overall survival from diagnosis was 24 months, an

54 Median overall survival from random assignment was longe

55 Median overall survival from the date of the first rando

56 With a median follow-up of 36.7 months, the median overall survival from the date of the first rando

57 The median overall survival from the first (90)Y treatment w

58 Median overall survival from the first SIRT was 18 mo (9

59 Median overall survival from the start of chemotherapy w

60 Median overall survival from the start of FOLFIRINOX ran

61 Median overall survival from the time of surgery was 25.

62 was evident in epithelioid histology, with a median overall survival gain of 5.4 months (HR, 0.70; 95

63 FS (GemErlo 11.4 months; Gem 11.4 months) or median overall survival (GemErlo 24.5 months; Gem 26.5 m

64 ration between 4 and 8 weeks had the longest median overall survival (group B: 40.4 months) compared

65 In the ITT population, median overall survival had an HR of 0.93 (0.76-1.14) an

66 Median overall survival had not been reached in either g

67 6.8) for those assigned to ipilimumab alone; median overall survival had not been reached in either g

68 At a minimum follow-up of 36 months, the median overall survival had not been reached in the nivo

69 Median overall survival has not been reached in any of t

70 Median overall survival has not been reached in either g

71 an follow-up of approximately 23 months, the median overall survival has not been reached in either s

72 Median overall survival has not been reached.

73 The median overall survival has yet to be reached with a med

74 ponse, median progression-free survival, and median overall survival have not been reached.

75 Median overall survival in all randomly assigned patient

76 The median overall survival in cohort A was 18.5 months in t

77 f 50.3 months (IQR 32.9-68.0), the estimated median overall survival in group A has not been reached,

78 Median overall survival in group I, II, and III was 29,

79 ggest that S70pBcl2 is associated with lower median overall survival in lymphoma patients.

80 In addition, median overall survival in ophthalmic-only disease was h

81 After 313 events, median overall survival in patients assigned nanoliposom

82 We compared median overall survival in patients with actionable muta

83 ance therapy until progression, improved the median overall survival in patients with platinum-sensit

84 Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevaciz

85 Median overall survival in the intention-to-treat patien

86 Median overall survival in the intention-to-treat popula

87 Median overall survival in the intention-to-treat popula

88 Estimated median overall survival in the once-a-week arm was 39.5

89 er a median follow-up time of 11 months, the median overall survival in the RT cohort was 10.7 months

90 Median overall survival in treated patients with PEL was

91 22.4 months (95% CI, 5.4 to 37.6 months) and median overall survival is 34.8 months (95% CI, 14.8 mon

92 n patients with advanced soft-tissue and the median overall survival is only 18 months.

93 reliably identifies the 5% of patients with median overall survival less than 2 years, significantly

94 median progression-free survival (mPFS) and median overall survival (mOS) times than patients who re

95 CR + CRi (all patients) was 11.3 months, and median overall survival (mOS) was 17.5 months; mOS has n

96 in patients with sensitising EGFR mutations (median overall survival NE [95% CI NE-NE] with ABCP [26

97 n improved the outcomes of patients with HT (median overall survival, not reached v 1.7 years) but no

98 tio 1.06, 95% CI 0.88-1.29; p=0.527), with a median overall survival of 18.4 months (95% CI 15.6-22.1

99 -23.4) for previously treated patients, with median overall survival of 22.3 months (95% CI 17.1-31.5

100 h progression-free survival rate of 35%, and median overall survival of 23 months; grade 3 or 4 treat

101 normal AFP levels (<13 ng/dL) and exhibited median overall survival of 23.9 mo (95% CI, 20.1-124.1 m

102 ) across studies with a pooled patient-level median overall survival of 24.2 months (95% CI 21.7-26.8

103 73 days, while untreated leukemic mice had a median overall survival of 34 days (P < .001, Mantel-Cox

104 total of 2698 patients were included with a median overall survival of 34 months (range 4-143).

105 This systematic review showed a median overall survival of 40% for patients with OHCA tr

106 with 261 deaths among 345 women (76%) and a median overall survival of 42.0 months in the anastrozol

107 p had 247 deaths among 349 women (71%) and a median overall survival of 49.8 months, as compared with

108 se rate of 100% or 73%, respectively, with a median overall survival of 5.2 years.

109 CP-B7 and >/=CP-B8 patients exhibited median overall survival of 6.9 mo (95% CI, 5.3-10.1 mo)

110 treated with 200 muCi (90)Y-DOTA-30F11 had a median overall survival of 73 days, while untreated leuk

111 ree survival of 62 d (range, 29-110 d) and a median overall survival of 76 d (range, 29-334 d).

112 atients with recurrent disease (n = 4) had a median overall survival of 8.5 months.

113 (PSC) are a rare group of lung cancer with a median overall survival of 9-12 months.

114 The median overall survival of all patients after the first

115 The median overall survival of all patients was 21.7 months

116 iloleucel can induce durable responses and a median overall survival of greater than 2 years, and has

117 ts with Ewing sarcoma or osteosarcoma have a median overall survival of less than 12 months after dia

118 phoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months.

119 The prognosis of EMM is poor, and the median overall survival of patients who experience an ex

120 The median overall survival of patients with high-risk myelo

121 Median overall survival of the cohort was 24.2 months.

122 Median overall survival (OS) after MPE diagnosis was 9 m

123 The median overall survival (OS) and recurrence free surviva

124 viral vector-based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placeb

125 The median overall survival (OS) following cessation of ibru

126 The median overall survival (OS) for all patients was 64 mon

127 eatic cancer have a dismal prognosis, with a median overall survival (OS) of 12-14 months with system

128 atients with >3 CTC/ml had a trend for worse median overall survival (OS) than patients with 0.3-3 CT

129 Median overall survival (OS) time after diagnosis was 30

130 The median overall survival (OS) time for the entire cohort

131 Median overall survival (OS) was 11.3 months (95% CI, 9.

132 Median overall survival (OS) was 12.3 months, and the OS

133 Median overall survival (OS) was 12.6 months with bevaci

134 Median overall survival (OS) was 18 months (95% CI, 8-27

135 t-free survival (hemEFS) was 11.8 months and median overall survival (OS) was 25.6 months.

136 The median overall survival (OS) was 30 months (95% confiden

137 Among 131 patients, the median overall survival (OS) was 30 months; 68 months fo

138 Median overall survival (OS) was 34.2 months from diagno

139 or those receiving Kd56 vs Vd, respectively; median overall survival (OS) was 42.1 vs 23.7 months (HR

140 Median overall survival (OS) was 81 months for BRAF-wt a

141 Median overall survival (OS) was NR; 1-year OS was 67% (

142 sion in PC patients is associated with worse median overall survival (OS).

143 using point estimates for weighted values of median overall survival, progression-free survival, resp

144 Median overall survival since diagnosis was 31.5 months

145 ly significant improvement of 11.8 months in median overall survival, suggesting a potential shift in

146 ched therapy (n=46) had significantly longer median overall survival than did those patients who only

147 diation therapy plus chemotherapy had longer median overall survival than did those who received radi

148 rogen-deprivation therapy resulted in longer median overall survival than placebo plus androgen-depri

149 ved molecularly matched therapy had a longer median overall survival than similar patients who did no

150 ry, or distal CBD adenocarcinomas had longer median overall survival than those with PB type (71.7 vs

151 pectively (hazard ratio, 0.91; P = .18), and median overall survival time was 3.9 years in both treat

152 The median overall survival was 1.035 years.

153 Estimated median overall survival was 1.43 years (95% confidence i

154 The median overall survival was 10.3 versus 8.9 months (stra

155 atio [HR] 0.82 [95% CI 0.68-1.00]; p=0.045); median overall survival was 10.4 months (95% CI 9.6-12.0

156 Median overall survival was 10.4 months for SRS alone an

157 In the total population, median overall survival was 10.4 months with pembrolizum

158 For the entire study cohort, median overall survival was 11.1 months (95% CI, 4.1-27.

159 The median overall survival was 11.1 months in the ruxolitin

160 Median overall survival was 11.4 mo (95% confidence inte

161 ective response rate was 45% versus 31%, and median overall survival was 11.5 versus 8.5 months (HR,

162 rogression-free survival was 4.2 months, and median overall survival was 11.6 months at a median foll

163 Median overall survival was 11.6, 8.6, and 11.8 months;

164 Median overall survival was 11.9 months (95% CI, 5.6 to

165 -free survival was 7.0 months (5.7-9.0), and median overall survival was 12.0 months (9.2-17.0).

166 Median overall survival was 12.3 months for cisplatin pl

167 -up of 23.5 months (range, 0.6-40.9 months), median overall survival was 12.6 months (95% CI, 4.5-25.

168 Median overall survival was 12.6 years, and conditional

169 0.75 [95% CI 0.62-0.91]; nominal p=0.0032); median overall survival was 12.9 months (95% CI 11.3-14.

170 ratio of 0.73 (95% CI 0.59-0.91; p=0.0047]); median overall survival was 13.0 months (95% CI 11.5-14.

171 At a median follow-up of 31.4 mo, median overall survival was 13.3 mo (95% CI, 10.5-18.7 m

172 For colorectal cancer patients (n = 23), the median overall survival was 13.4 mo (95% CI, 8.2-15.7 mo

173 The median overall survival was 13.4 months (95% CI, 7.7 to

174 The median overall survival was 13.6 months with cabazitaxel

175 Median overall survival was 13.8 months (95% CI 11.1-29.

176 d with atezolizumab compared with docetaxel (median overall survival was 13.8 months [95% CI 11.8-15.

177 In the high PD-L1 population, median overall survival was 14.4 months (95% CI 10.4-17.

178 nterval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 mont

179 The median overall survival was 14.5 mo (95% CI, 8.6-22.8 mo

180 In the intention-to-treat population, median overall survival was 15.1 months (13.1-18.0) in t

181 Median overall survival was 15.3 months after resection

182 Median overall survival was 15.7 months (13.1-17.8) for

183 Median overall survival was 15.7 months (95% CI 11.6-17.

184 umab (n=241) compared with docetaxel (n=222; median overall survival was 15.7 months [95% CI 12.6-18.

185 Median overall survival was 15.9 months (10.4 to not est

186 Median overall survival was 15.9 months for doxorubicin

187 ths (IQR 5-11) and 210 deaths were reported; median overall survival was 16 months (95% CI 13-not ava

188 Median overall survival was 16.0 months (13.9-18.9) in g

189 val was 6.0 (95% CI, 5.0 to 7.3) months, and median overall survival was 16.6 (95% CI, 11.1 to 20.6)

190 Median overall survival was 16.9 months (95% CI 1.5-32.3

191 follow-up was 6.5 (IQR 3.8-10.0) years, and median overall survival was 16.9 months (95% CI 16.2-17.

192 the ipilimumab followed by nivolumab group, median overall survival was 16.9 months (95% CI 9.2-26.5

193 Median overall survival was 17.3 months.

194 rvival was 8.8 (95% CI, 4.6-15.4) months and median overall survival was 17.5 (95% CI, 13.3-NE) month

195 % CI 51.2-75.5) and, at a subsequent cutoff, median overall survival was 17.5 months (95% CI 13.7-not

196 ion was 11 months (95% CI, 9-13 months), and median overall survival was 18 months (95% CI, 9-27 mont

197 The median overall survival was 18.1 months (95% CI 10.0-not

198 The median overall survival was 18.2 months (95% CI, 11.3 to

199 The median overall survival was 18.54 months (95% CI 10.81-2

200 objective response rate was 25% and 10%, and median overall survival was 19.0 and 15.2 months, respec

201 urvival was 5.5 months (95% CI 3.4-5.9), and median overall survival was 19.0 months (11.0-not estima

202 Median overall survival was 20 mo (interquartile range,

203 e in overall survival for patients with MRD: median overall survival was 20.1 months (95% CI 18.5-22.

204 Median overall survival was 20.5 months (95% CI 16.6-28.

205 Median overall survival was 21.4 months (95% CI 13.8-NE)

206 Median overall survival was 21.4 months (95% CI 18.7-not

207 Median overall survival was 21.9 months (95% CI, 15.1 mo

208 6; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months,

209 Median overall survival was 22 months (95% CI, 12.9 mont

210 Median overall survival was 22.9 months (95% CI, 16.5 to

211 (95% CI, 2.0 months to 10.7 months), and the median overall survival was 24.9 months (95% CI, 4.2 mon

212 Median overall survival was 25 months (95% CI, 12-32 mon

213 nts with PD-L1 immune cell-positive tumours, median overall survival was 25.0 months (95% CI 19.6-30.

214 ing bortezomib and an immunomodulatory drug, median overall survival was 25.5 months (95% CI 19.6-34.

215 onths (T,: 16.6 months; TC, 5.6 months), and median overall survival was 25.7 months (T, not reached;

216 7.5 months (95% CI, 8.6-25.0 months) and the median overall survival was 25.8 months (95% CI, 15.7-25

217 Median overall survival was 26.5 months (20.9-31.7) with

218 Median overall survival was 28 [95% confidence interval

219 Median overall survival was 28 months (95% CI 19-33) in

220 Median overall survival was 28 months.

221 The median overall survival was 28.6 months.

222 The median overall survival was 28.7 months, and the median

223 old for statistical significance [p<0.0095]; median overall survival was 29.8 months [95% CI 26.9-35.

224 a median follow-up of 45 months (IQR 35-58), median overall survival was 30 months (95% CI 24-34) in

225 The median overall survival was 30.0 months in the cetuximab

226 In treatment-naive patients, median overall survival was 31 months (95% CI, 24 to not

227 The median overall survival was 31.3 months (95% CI, 18.9-up

228 ree survival was 17 mo (range, 0-30 mo), and median overall survival was 32 mo (range, 4-53 mo).

229 onths (IQR 56.7-59.2) in surviving patients, median overall survival was 32.7 months (95% CI 24.5-41.

230 The median overall survival was 36.7 mo (95% confidence inte

231 Among propensity score-matched groups, the median overall survival was 37.3 (95% CI, 35.2-38.7) mon

232 The median overall survival was 39 months, and there were no

233 The median overall survival was 4.3 years, and the median ev

234 Median overall survival was 40.3 months (95% CI 35.0-44.

235 % confidence interval, 6.9 to 8.5 weeks) and median overall survival was 42.6 weeks (95% confidence i

236 Median overall survival was 47.6 months (95% CI 42.5-not

237 Median overall survival was 5.9 months (95% CI 4.8-7.8)

238 In the intention-to-treat analysis, median overall survival was 51.1 months (95% CI 34.6-59.

239 ine group and 220 in the observation group), median overall survival was 53 months (95% CI 40 to not

240 Median overall survival was 57.1 months (95% CI 50-72) i

241 t patients versus all TERTp-wt patients, the median overall survival was 58 months and 160 months, re

242 Median overall survival was 6.2 months (5.3-7.2) in the

243 te, 7%) to the next line of therapy, and the median overall survival was 6.3 months.

244 Median overall survival was 6.5 months, 9.0 and 5.1 mont

245 Median overall survival was 6.6 years (95% CI, 5.5 to 7.

246 iotherapy groups, respectively (p=0.58), and median overall survival was 6.9 months (95% CI 5.1-8.3)

247 The median overall survival was 61.2 (interquartile range [I

248 Median overall survival was 67.0 months (95% confidence

249 Median overall survival was 7.5 months in mesenchymal ve

250 The median overall survival was 7.7 months in the blinatumom

251 Median overall survival was 7.9 months (95% CI 6.7-9.5)

252 Median overall survival was 71 months (IQR 32 to not rea

253 Results: Median overall survival was 79 mo.

254 rogression-free survival was 2.1 months, and median overall survival was 8 months.

255 Median overall survival was 8.2 months with ATRA v 5.1 m

256 patients, the response rate was 67%, and the median overall survival was 8.5 months.

257 rogression-free survival was 3.7 months, and median overall survival was 8.6 months.

258 Median overall survival was 8.7 months (IQR, 3.6-16.8) w

259 Median overall survival was 8.8 months (95% CI 7.7-10.2)

260 Median overall survival was 8.8 months (95% CI, 7.7-9.6)

261 The median overall survival was 8.8 months for Ona + Bev and

262 The median overall survival was 8.83 months (95% CI 7.11-11.

263 Median overall survival was 8.87 months (95% CI 7.00-10.

264 Median overall survival was 81.0 months (59.6 to not rea

265 oxorubicin groups for the efficacy analysis, median overall survival was 9.1 months (95% CI 8.1-10.4)

266 py did not provide a survival advantage; the median overall survival was 9.1 months (95% confidence i

267 Median overall survival was 9.2 months for patients rand

268 Median overall survival was 9.4 months (95% CI 7.9-11.4)

269 the 16 patients with mast-cell leukemia, the median overall survival was 9.4 months (95% CI, 7.5 to n

270 Median overall survival was also longer in patients who

271 The median overall survival was also significantly improved

272 patient, the primary outcome measurement of median overall survival was calculated from the initial

273 Median overall survival was compared between patients wi

274 Median overall survival was improved in the doublet arm

275 of overall survival with predefined factors, median overall survival was longer for: patients with ba

276 In this final descriptive analysis, median overall survival was longer with trastuzumab emta

277 Median overall survival was lower in PVRL (38.0 months;

278 At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (media

279 In EGFR-positive patients (124 of 1202), median overall survival was not estimable (NE; 95% CI 17

280 The median overall survival was not reached (12.8-not estima

281 Median overall survival was not reached (95% CI 12.9-not

282 Median overall survival was not reached (95% CI, 10.7 mo

283 was 9.1 months (95% CI, 4.9 to 11.7 months); median overall survival was not reached at 14 months.

284 Median overall survival was not reached at the median fo

285 ogression-free survival was 13.7 mo, and the median overall survival was not reached during follow-up

286 Median overall survival was not reached for treated pati

287 Median overall survival was not reached in either group.

288 Median overall survival was not reached in either pembro

289 an follow-up of 19.8 months (IQR 12.8-25.7), median overall survival was not reached in the nivolumab

290 8.3 months (95% CI, 6.0 to15.1 months), and median overall survival was not reached.

291 Median overall survival was not significantly different

292 In the experimental arm, median overall survival was shorter (3.9 vs 6.7 months;

293 patients treated with platinum chemotherapy, median overall survival was significantly longer for pat

294 Across all patients, median overall survival was significantly longer if 7-mo

295 Median overall survival was significantly longer in pati

296 Median overall survival was similar between both arms wi

297 Median overall survival was superior in the salvage ASCT

298 n a significant but only marginally improved median overall survival when combined with gemcitabine i

299 Improved median overall survival with ABCP versus BCP was seen in

300 Conclusion The target median overall survival with CT-guided percutaneous irre